Skip to main content

Table 1 Selected baseline patient and disease characteristics

From: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program

  FAS population
Age (years): median (range) 64 (25–91)
Age (years): n (%)
 < 65 343 (52.4)
 ≥ 65 311 (47.6)
BMI (Kg/m2) 24 (14.1–49.1)
ECOG Performance Status: n (%)
 0 200 (30.7)
 1 383 (58.7)
 2 60 (9.2)
 3 9 (1.4)
 Missing 2
Site of Primary tumour: n (%)
 Colon 445 (69.9)
 Rectum 186 (29.9)
 Colon and rectum 5 (0.2)
 Missing 18
Timing of metastases: n (%)
 Synchronous 416 (65.6)
 Metachronous 218 (34.4)
 missing 20
Delay from initial diagnosis of metastases (months): median (range) 31 (0.8–156.5)
Delay from initial diagnosis of metastases (months): n (%)
 < 18 134 (20.6)
 ≥ 18 518 (79.4)
 Missing 2
KRAS mutational status: n (%)
 Wild 291 (46.8)
 Mutated 331 (53.2)
 Missing 32
Initial dose of REG, mg/d, 3 w/4: n (%)
 40 3 (0.5)
 80 39 (6)
 120 89 (13.6)
 160 522 (79.9)
 Missing 1